Last reviewed · How we verify
Syntommetrine and Carbetocin
Syntommetrine and Carbetocin is a Uterotonic agent Small molecule drug developed by National University Hospital, Singapore. It is currently FDA-approved for Prevention and treatment of postpartum hemorrhage, Active management of the third stage of labor.
Syntommetrine (ergot alkaloid + oxytocin combination) and Carbetocin (oxytocin analogue) stimulate uterine muscle contraction to prevent or treat postpartum hemorrhage.
Syntommetrine (ergot alkaloid + oxytocin combination) and Carbetocin (oxytocin analogue) stimulate uterine muscle contraction to prevent or treat postpartum hemorrhage. Used for Prevention and treatment of postpartum hemorrhage, Active management of the third stage of labor.
At a glance
| Generic name | Syntommetrine and Carbetocin |
|---|---|
| Sponsor | National University Hospital, Singapore |
| Drug class | Uterotonic agent |
| Target | Oxytocin receptor |
| Modality | Small molecule |
| Therapeutic area | Obstetrics |
| Phase | FDA-approved |
Mechanism of action
Syntommetrine combines ergotamine (which causes sustained uterine contraction) with oxytocin (which triggers rhythmic contractions). Carbetocin is a synthetic oxytocin analogue with longer duration of action and greater stability. Both work by binding oxytocin receptors on uterine smooth muscle, promoting sustained contraction to compress bleeding vessels and control hemorrhage after delivery.
Approved indications
- Prevention and treatment of postpartum hemorrhage
- Active management of the third stage of labor
Common side effects
- Hypertension
- Nausea and vomiting
- Headache
- Uterine cramping
- Coronary vasospasm (ergot-containing formulations)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Syntommetrine and Carbetocin CI brief — competitive landscape report
- Syntommetrine and Carbetocin updates RSS · CI watch RSS
- National University Hospital, Singapore portfolio CI
Frequently asked questions about Syntommetrine and Carbetocin
What is Syntommetrine and Carbetocin?
How does Syntommetrine and Carbetocin work?
What is Syntommetrine and Carbetocin used for?
Who makes Syntommetrine and Carbetocin?
What drug class is Syntommetrine and Carbetocin in?
What development phase is Syntommetrine and Carbetocin in?
What are the side effects of Syntommetrine and Carbetocin?
What does Syntommetrine and Carbetocin target?
Related
- Drug class: All Uterotonic agent drugs
- Target: All drugs targeting Oxytocin receptor
- Manufacturer: National University Hospital, Singapore — full pipeline
- Therapeutic area: All drugs in Obstetrics
- Indication: Drugs for Prevention and treatment of postpartum hemorrhage
- Indication: Drugs for Active management of the third stage of labor
- Compare: Syntommetrine and Carbetocin vs similar drugs
- Pricing: Syntommetrine and Carbetocin cost, discount & access